書誌事項
- タイトル別名
-
- Basic and clinical studies on ritipenem acoxil
この論文をさがす
抄録
We performed bacteriological and clinical studies on ritipenem acoxil (RIPM-AC), a new oral penem antibiotic, with the following results.<BR>1. The MIC90 of ritipenem (RIPM) against Staphylococcus aureus was 0.25 μg/ml, second to that of imipenem/cilastatin Na (IPM/CS) and superior to those of cefotiam (CTM), cefixime CFIX), cefpodoxime (CPDX) and ampicillin (ABPC). The MIC90, against Streptococcus pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae and Moraxella catarrhalis were 2 μg/ml, 1 μg/ml, 0.5 μg/ml and 1 μg/ml, respectively. RIPM was, however, weak against methicillin-resist ant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.<BR>2. Twelve patients with respiratory infections were treated with RIPM-AC. The overall efficacy rate was 81.8%(excellent 1, good 8, fair 1, poor 1, unkown 1). No clinical side effects were observed, but elevation of S-GOT was observed in 2 cases after treatment.
収録刊行物
-
- 日本化学療法学会雑誌
-
日本化学療法学会雑誌 43 (Supplement3), 160-164, 1995
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206286808192
-
- NII論文ID
- 10005467408
- 130004297341
-
- NII書誌ID
- AN10472127
-
- ISSN
- 18845886
- 13407007
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可